What is new in the pathogenesis and treatment of IgA glomerulonephritis

doi:10.5527/wjn.v13.i4.98709

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (842)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

HTML

411

Figures (1-4)

Tables (1-4)

110

Sum=604

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=148

Publishing Process of This Article

Item

Count

Browse

Download

Sum=68

Dec 25, 2024 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Nephrol. Dec 25, 2024; 13(4): 98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709

Open in New Tab Full Size Figure Download Figure

Figure 1 Targeting regulating genes. MTMR3: Myotubularin related protein 3; TLR9: Toll like receptor 9.

Open in New Tab Full Size Figure Download Figure

Figure 2 Induction of IgA nephropathy.

Open in New Tab Full Size Figure Download Figure

Figure 3 Potential targets for IgA nephropathy based on findings from genetic wide association studies. ETAR: Endothelin angiotensin inhibitor; SGLT2: Sodium-glucose cotransporter; MRA: Mineralocorticoid receptor antagonists; AP: Alternative pathway; LP: Lectin pathway; CP: Classical pathway.

Open in New Tab Full Size Figure Download Figure

Figure 4 Treatment for IgA nephropathy. SGLT2: Sodium-glucose cotransporter; MRA: Mineralocorticoid receptor antagonists; GLP-1: Glucagon-like peptide-1; CKD: Chronic kidney disease; DEARA: Dual endothelial angiotensin receptor antagonist.

Citation: Salvadori M, Rosso G. What is new in the pathogenesis and treatment of IgA glomerulonephritis. World J Nephrol 2024; 13(4): 98709
URL: https://www.wjgnet.com/2220-6124/full/v13/i4/98709.htm
DOI: https://dx.doi.org/10.5527/wjn.v13.i4.98709